Trial Profile

A Pivotal, Phase III trial of Oral KORSUVA for the Treatment of Pruritus in Non-Hemodialysis CKD-aP Patients

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 10 Mar 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Difelikefalin (Primary)
Indications Pruritus
Focus Adverse reactions; Registrational; Therapeutic Use
Sponsors Cara Therapeutics

Most Recent Events

18 Feb 2022 According to a Cara Therapeutics media release, the Company will host a virtual research and development (R&D) event focusing on the initiation of this trial on March 11, 2022.
08 Nov 2021 According to a Cara Therapeutics media release, this trial is expected to begin in the first quarter of 2022.
09 Aug 2021 According to a Cara Therapeutics media release, the company plans to meet with the FDA in the fourth quarter of 2021, to discuss the potential inclusion of earlier stage CKD patients in a Phase 3 program.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com